Reuters logo
BRIEF-Cellectis announces first patient dosed in clinical trial on UCART123
August 18, 2017 / 6:56 AM / a month ago

BRIEF-Cellectis announces first patient dosed in clinical trial on UCART123

Aug 18(Reuters) - CELLECTIS SA:

* ANNOUNCED ON THURSDAY, UCART123‘S ADMINISTRATION TO FIRST PATIENT WITH BPDCN IN PHASE I CLINICAL TRIAL AT MD ANDERSON CANCER CENTER

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below